FDA Compliance· Jun 11, 2026
Unresolved Anomalies in FDA Cybersecurity Filings
What the FDA's Feb 2026 guidance expects in the unresolved cybersecurity anomalies assessment, how to document residual risk, and the deficiency pattern.
Read articleEvery article in our archive tagged Residual Risk.
Looking for a quick answer instead? The FDA medical device cybersecurity FAQ covers Section 524B scope, SBOMs, threat models, CR515 and GMLP, deficiencies, and postmarket duties.
Showing 1 of 1 article tagged Residual Risk
What the FDA's Feb 2026 guidance expects in the unresolved cybersecurity anomalies assessment, how to document residual risk, and the deficiency pattern.
Read article30-minute strategy session. No cost, no commitment - just answers from people who've shipped 275+ devices supported.